The immune checkpoint blockade (ICB) targeting the programmed cell death receptor-1 (PD-1) and PD-L1 axis alone or in association with the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade brought durable clinical responses for clear cell renal cell carcinoma (ccRCC) in adjuvant settings and metastatic scenarios, becoming an important pillar treatment [2,3,4]. The gene discussed is CTLA4; the disease is clear cell renal carcinoma.